Evaluation of Safety, efficacy, and QOL with Glecaprevir and Pibrentasvir therapy in Dialysis Patients Infected with Hepatitis C Virus
Not Applicable
Recruiting
- Conditions
- Chronic hepatitis-C, Chronic Renal failure
- Registration Number
- JPRN-UMIN000030229
- Lead Sponsor
- Kasama Chuo Clinic
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Depends on insurance adaptation
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sustained Virological Response at 12weeks after treatment
- Secondary Outcome Measures
Name Time Method Safety and QOL during 6 months after treatment, and the period of treatment